Two pharmaceutical manufacturing companies recently warned doctors of two deaths among patients receiving Rituxan as a treatment for lupus. Usually used to treat patients with non-Hodgkin’s lymphoma and rheumatoid arthritis, the drug is not currently approved as a therapy for lupus.
The patients who had received the drug developed a rare brain infection called progressive multifocal leukoencephalopathy. The FDA posted a public health advisory on its Web site after the two deaths.
For the full article.